ASA. Yu. Smirnova

A. Yu. Smirnova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


A. Yu. Smirnova has a total of 107 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of quality of life in patients who underwent antineoplastic therapy for central nervous system malignancies in childhood

    by Yu. V. Dinikina, N. V. Muliarova, V. V. Chernikov, I. L. Nikitina, O. G. Zheludkova, I. A. Kelmanson, A. Yu. Smirnova, N. G. Goikalov, I. V. Vinyarskaya

    Background . According to international statistics tumors of the central nervous system take a leading position in the structure of childhood cancer morbidity. The use of a multimodal strategy of anticancer therapy today allows achieving a high level of long-term survival, but often with severe variants of long-term toxicity. The study of the health status of cured patients and assessment of their quality of life (QOL) in the aspects of searching for controllable factors to reduce treatment toxicity is a pressing problem in pediatric oncology and pediatrics. Materials and methods . The study included 76 patients with a confirmed diagnosis of medulloblastoma (93.4 %) or atypical teratoid rhabdoid tumor (6.6 %), established at the age of up to 18 years, for which antitumor therapy was carried out. For assess to QOL, the Health Utilities Index questionnaire of Mark 2 and 3 versions (HUI2 and HUI3) was used, consisting of 15 questions. The impact of disease burden (histological tumor type, stage and type (primary tumor/relapse) of the disease, inclusion of high-dose chemotherapy, volume of radiation therapy and surgery) on the health attribute scores was analyzed. Results . The median age of patients at the time of the survey was 11.7 years with a median interval after completion of specific treatment of 6.4 years. Respondents to the survey were patients’ parents (n = 37; 48.7 %) and/or the attending physician monitoring the child (n = 39; 51.3 %). The average time spent on filling out the questionnaire was 8.0 ± 3.0 min. The frequency of a decrease in the levels of health attributes according to the HUI2 and HUI3 systems were 47% and 53 %, corresponding to mild (66 % and 62 %), moderate (27 % and 26 %) and severe (7 % and 12 %) severity of disorders. Functional health disorders mostly concerned such QOL components as cognitive abilities, emotions, sensation, mobility, varying from moderate to severe. Metastatic stage of the tumor had statistically significant negative impact on mobility and ambulation (p = 0.02), self-care (p = 0.05) and dexterity (p = 0.01); patients with disease recurrence showed decreased cognition (p = 0.03) and emotional status (p = 0.002); the use of craniospinal irradiation was also associated with decreased cognitive abilities (p = 0.04). Conclusions . Assessment of patients’ QOL using the HUI2 and HUI3 questionnaire is a simple and accessible method for routine use in clinical practice. Statistically significant deviations in health attributes were registered in children who underwent antitumor therapy for medulloblastoma or atypical teratoid rhabdoid tumor, while unfavorable risk factors were disease recurrence, metastatic stage of the disease and radiation therapy in the CSI. It is important to note that despite the high percentage of recorded deviations in the assessed health attributes, more than half of them corresponded to mild to moderate impairments. The most vulnerable components were the motor sphere and cognitive abilities. Given the small sample size, it is impossible to speak about a high degree of significance of the obtained results, which requires continuation of research in the specified cohort of patients, however, they coincide with international literature data. It should also be noted that the questionnaire provides an assessment of the health status of patients in a specific period, while it can change significantly over time and against the background of numerous factors, thereby determining the need for dynamic monitoring.

  • Open Access

    Tandem hematopoietic stem cell transplantation in children with solid tumors in the Russian Federation: results of a retrospective multicenter study

    by D. S. Smirnova, K. I. Kirgizov, I. V. Kazantsev, S. A. Kulyova, P. S. Tolkunova, Yu. V. Dinikina, A. Yu. Smirnova, S. I. Lapaeva, T. Z. Aliev, G. B. Sagoyan, et al.

    Relevance. Despite the overall decline in the use of auto-HSCT, there remains a need for treatment intensification in pediatric patients with highrisk solid tumors. Tandem auto-HSCT represents a promising approach to improve therapeutic efficacy, but its toxicity and impact on long-term outcomes require further investigation, particularly in the Russian patient population.The aim of study – to evaluate the feasibility, toxicity, and long-term outcomes of tandem autologous hematopoietic stem cell transplantation (auto-HSCT) in children with high-risk solid malignant neoplasms in the Russian Federation.Materials and methods. This retrospective multicenter study included 108 (100 %) pediatric patients (median age – 2 years) with solid malignant neoplasms who underwent tandem high-dose chemotherapy with auto-HSCT at 9 centers in the Russian Federation (2004–2024). Main diagnoses included brain tumors – n = 66 (61.1 %), germ cell tumors – n = 25 (23 %), and neuroblastoma – n = 12 (11.1 %). Toxicity was assessed using CTCAE v5.0 criteria, and survival analysis was performed using the Kaplan–Meyer method.Results. The most common complications were febrile neutropenia (88.9 %) and oropharyngeal mucositis (87.1 %), with severe toxicities (Grade 3–4) being rare. The 3-year overall survival was 72.2 %, and event-free survival was 62.7 %.Conclusion. The study demonstrated that tandem auto-HSCT is a feasible procedure with manageable toxicity. These findings suggest the potential of tandem auto-HSCT for children with high-risk solid tumors, though further prospective studies with long-term outcome assessments are needed to define optimal indications.


  • Open Access

    Diagnostic aspects of pediatric embryonal tumors of the central nervous system: what should know pediatrician

    by Yu. V. Dinikina, A. Yu. Smirnova, N. N. Osipov, Д. М. Спельников, D. A. Morgacheva, O. G. Zheludkova, M. B. Belogurova, I. L. Nikitina

    Background. Early identification of pediatric central nervous system (CNS) tumors is important in relation to disease prognosis, as well as long-term treatment outcomes, which determine subsequent quality of life. The predominance of embryonal tumors (ETs) in early childhood actualizes the problem of timely verification of the diagnosis. Factors contributing to the extension of diagnostic time in the presented patient’s cohort include the inability to adequately verbalize complaints in young children, a wide range of clinical presentations, including nonspecific ones, the relatively low incidence of ET in the population and the low level of oncological alertness among specialists. This determines the need for a more careful assessment of the clinical manifestations and disease-associated symptoms by doctors of all specialties and, especially, primary care specialists. Aim. Analysis of clinical symptoms at the disease’s onset in pediatric CNS ET in order to determine their associations with the tumor’s characteristics (site, hystologic type) and the patient’s features. Materials and methods. A retrospective analysis of data from 124 pediatric patients with CNS ET who received treatment from 2010 to 2023 in the departments of pediatric oncology of the Almazov National Medical Research Center and the St. Petersburg Scientific Research Center for Medical Sciences (o) named after. N. P. Napalkov. The analyzed parameters were the age of manifestation, initial symptoms, duration of the anamnesis and the period before verification of the diagnosis, localization and histological type of tumors. For statistical analysis, Fisher’s exact test, modified Pearson test, Kruskal-Wallis and Mann-Whitney tests, as well as (to assess the duration of anamnesis) the Cox model were used. Results. The most common type of CNS ET in the study group was medulloblastoma (MB; 66.1%). The average age of patients, in general, was 61 months, boys predominated (58%). The median age varied depending on the histological tumor type: the maximum was 72 months in patients with medulloblastoma and the minimum was 9 months in children with atypical teratoid rhabdoid tumor (ATRT). Both medians are significantly different from the total median (29 months) of all other tumors (p = 6.53 ∙ 10-4 and p = 0.029, respectively). The most frequent symptoms in patients with ET were nausea and vomiting (68%), headache (50%), and gait disturbances (25.6%). Increased head circumference/bulging fontanel (p = 0.0016) and torticollis (p = 0.0057) were the most common symptoms associated with younger age. Headache (p = 1.30 ∙ 10-9), nausea and vomiting (p = 0.019), diplopia (p = 0.0057), weight loss (p = 0.017) and dizziness (p = 0.013) were associated with older age. Headache was predominated symptom in medulloblastoma (p = 2.60 ∙ 10-4) compared to other ETs, and less common in ATRT (p = 1.51 ∙ 10-4), which may be due to the patient’s age. Fontanel bulging in medulloblastoma, unlike other ET, was not observed, which is also associated with age. Seizures were observed in all cases of CNS neuroblastoma - significantly more often (p = 0.034) than in other ETs. The most common tumor location was the posterior cranial fossa (PCF) (83.6%). PCF localization was associated with headache (p = 0.05, borderline significance) and nausea/vomiting (p = 0.040). Parietal localization was associated with seizures (p = 0.041). Four patients in the cohort had asymptomatic disease’s manifestations. The diagnosis was established by a routine screening examination. The absence of symptoms was associated with location outside the PCF (p = 0.011) and with younger age (p = 0.053, borderline significance). The diagnosis was established in a significantly shorter time if children had symptoms such as nausea and vomiting (p=0.0017), paresis and paralysis (p=0.0059). Conclusion. In patients with CNS ETs, statistically significant relationships are revealed between age, histological type, tumor site and certain symptoms. Nevertheless, the absence of strictly specific clinical manifestation determines the indications for a careful assessment of the pediatric somatic and neurological status and timely neuroimaging in children when even potential symptoms typical for CNS tumors are identified.


  • Open Access

    Neurotrophic keratitis concomitant to CNS tumor in a child: clinical case

    by Юлия Константиновна Тошина, Ирина Викторовна Болотникова, Александр Евгеньевич Горкин, Анна Юрьевна Смирнова, Юлия Валерьевна Диникина

    Introduction. Neurotrophic keratitis (NK) is an orphan pathology caused by the damage of the trigeminal nerve with the subsequent degenerative changes of the corneal epithelium. Causes of NK include various genetic, systemic and infectious diseases, tumors of the central and peripheral nervous system, surgical interventions. Previously used methods of therapy were mostly symptomatic and did not allow to achieve complete restoration of corneal innervation and sensitivity. The use of topical cenegermin, a recombinant form of human nerve growth factor, in clinical practice allows significantly better control of NK in patients of all ages, regardless of the causative factor. Case description. We present a clinical case of NK in an early age patient with a recurrent form of atypical teratoid rhabdoid tumor (ATRT) of the central nervous system (CNS) with complete resolution of NK due to cenegermin therapy. Conclusion. Our experience demonstrates the efficiency, safety and feasibility of the method in an outpatient setting. Введение. Нейротрофический кератит (НК) представляет собой орфанную патологию, патогенез которой заключается в повреждении тройничного нерва с развитием последующих дегенеративных изменений роговицы. Причинами могут быть различные генетические, системные и инфекционные заболевания, опухолевые поражения центральной и периферической нервной системы, а также хирургическое вмешательство. Ранее применяемые методы терапии в большей степени носили симптоматический характер и не позволяли добиться полного восстановления иннервации и чувствительности роговицы. Применение в клинической практике препарата ценегермин, представляющего собой рекомбинантную форму человеческого фактора роста нервов, позволяет добиться значимо лучшего контроля над течением НК вне зависимости от причинного фактора у пациентов всех возрастов. Описание случая. Нами представлен клинический случай НК с достижением полной эпителизации роговицы на фоне применения ценегермина у пациентки раннего возраста с рецидивирующей формой атипической тератоидно-рабдоидной опухоли (АТРО) центральной нервной системы (ЦНС). Заключение. Наш опыт демонстрирует эффективность метода, а также его безопасность и возможность применения в амбулаторных условиях.


  • Open Access

    Atypical Teratoid Rhabdoid Tumor of Central Nervous System in an Infant: A Case Report

    by Анна Юрьевна Смирнова, Евгений Николаевич Суспицын, Евгений Наумович Имянитов, Маргарита Борисовна Белогурова, Юлия Валерьевна Диникина

    Introduction. Atypical teratoid rhabdoid tumors (ATRO) are extremely rare aggressive tumors of childhood with predominant occurrence in patients under 3 years of age and primary localization within the central nervous system (CNS). Despite intensive multimodal treatment approaches, the prognosis in this cohort of patients remains unsatisfactory. Case description. We present a case of an aggressive primary metastatic ATRT in combination with low-grade glioma in infant with rhabdoid tumor predisposition syndrome I (hereditary mutation in the SMARCB1 gene). The use of multimodal antitumor therapy according to the recommendations of the Medical University of Vienna (MUV ATRT) and metronomic chemotherapy was accompanied by a long-term effect. However, with the subsequent rapid progression of the disease, all treatment attempts were unsuccessful, and the patient died 44 months after diagnosis. Введение. Атипичные тератоид-рабдоидные опухоли (АТРО) являются чрезвычайно редкими агрессивными новообразованиями детского возраста с преимущественной встречаемостью у пациентов до 3 лет и доминирующей локализацией в пределах центральной нервной системы (ЦНС). Несмотря на интенсивные комплексные методы терапии, прогноз у данной категории больных остается неудовлетворительным. Описание случая. Нами представлен случай агрессивного течения первично-метастатической АТРО в сочетании с глиомой низкой степени злокачественности у пациентки первого года жизни с синдромом предрасположенности к рабдоидным опухолям I типа (наследственной мутацией в гене SMARCB1). Применение комплексной интенсивной противоопухолевой терапии, согласно рекомендациям Медицинского университета Вены (MUV ATRT) и метрономной химиотерапии, сопровождалось длительным эффектом. Тем не менее при последующем стремительном прогрессировании заболевания все попытки лечения оказались безрезультатными, и пациентка скончалась спустя 44 месяца после постановки диагноза.

  • Open Access

    Comparative treatment results of children with atypical teratoid/rhabdoid tumor of the central nervous system in the younger age group

    by L. V. Olkhova, O. G. Zheludkova, L. S. Zubarovskaya, A. S. Levashov, A. Yu. Smirnova, Yu. V. Dinikina, Yu. V. Kushel, A. G. Melikyan, S. K. Gorelyshev, M. V. Ryzhova, et al.

    Introduction. Atypical teratoid/rhabdoid tumor (ATRT) of the central nervous system (CNS) belongs to the embryonic group, occurs mainly in children under 3 years of age and is characterized by an extremely aggressive clinical course and unfavorable outcome. However, there is not enough data about the heterogeneity of the clinical course of CNS ATRT and the role of clinical and therapeutic prognostic factors in patients under 1 year of age and 1–3 years of age.The aim of this study was to conduct a comparative evaluation of treatment results in children with CNS ATRT in the indicated age groups.Materials and methods. From 2008 till 2021 years 106 patients were included in this study. Each patient underwent a therapeutic program according to determined protocol (ATRT-2006, MUV-ATRT, EU-RHAB and individual variant). All patients were divided into 2 groups according to age: from 1 to 12 months – 41 patients, from 13 to 36 months – 65. Median of the age was 16 (9–23) months. These cohorts of patients (1–12 months and 13–36 months) were comparable in clinical and therapeutic characteristics depending on gender, localization of the primary tumor site, stage of the disease, extent of surgical resection, therapeutic protocol, number of patients, who underwent radiation therapy (RT), high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplantation (auto-HSCT), intrathecal/ intraventricular chemotherapy.Results. At the time of analysis 48 (45.3 %) patients were alive, 58 (54.7 %) patients died, of whom 52 (90 %) from disease progression and 6 (10 %) from therapeutic complications. One-year progression-free survival (PFS) in the group from 1 to 12 months was 32 %, 2-year – 18 %, 5-year – 18 %; one-year overall survival (OS) – 53 %, 2-year – 29 %, 5-year – 25 % with a median follow-up 8 and 13 months respectively. One-year PFS in the group from 13 to 36 months was 61 %, 2-year – 36 %, 5-year – 33 %; one-year OS – 86 %, 2-year – 67 %, 5-year – 49 % with a median follow-up 19 and 38 months respectively. In our study we identified the main predictors of the PFS and OS improvement in patients with ATRT CNS of each age group. In the 1–12 month group, these factors were: absence of metastatic involvement, MUV-ATRT therapeutic protocol, RT and HDCT with auto-HSCT; in the 13–36 months group: gross total/near gross total resection of the primary tumor cite, ATRT-2006 therapeutic protocol and RT.Conclusion. Despite the fact, that the presence of a diagnosis of ATRT CNS in children under 3 years of age is usually associated with a high risk of disease progression and recurrence, the results of our study demonstrate the heterogeneity of the clinical and therapeutic profile in this age group of patients.


  • Open Access

    Priapism at the onset of acute lymphoblastic leukemia in a 12-year-old child

    by A. D. Inyoshina, А. S. Kapustina, А. Yu. Smirnova, Е. А. Гринь, G. G. Baratashvili, I. М. Kagantsov, Yu. V. Dinikina

    Acute lymphoblastic leukemia (ALL) is the most common cancer in the clinical practice of pediatric oncology/hematology. At the onset of the disease, patients can develop such a life-threatening complication as hyperleukocytosis with leukostasis that can manifest in many different ways, including ischemic priapism, an extremely rare type of leukostasis in children with ALL. Apart from death associated with hyperleukocytosis caused by the underlying disease, inadequate and poorly timed specific therapy and supportive care can lead to erectile dysfunction, impotence or intermittent priapism in the future. In this article, we report an extremely rare clinical case of ischemic priapism in a 12-year-old patient that developed at the onset of ALL and was the only manifestation of the disease as well as the reason for admission to hospital. The patient's parents gave consent to the use of their child's data, including photographs, for research purposes and in publications. Here, we analyzed special aspects of this complication, described modern treatment strategies and provided an international literature review. We emphasize the importance of urgent care delivery due to the critical prognostic significance of timely and adequate treatment provided by a multidisciplinary team.


  • Open Access

    Proton beam therapy in pediatric patients with central nervous system tumors: method features, clinical data analysis

    by А. Yu. Smirnova, G. G. Radulesku, N. А. Vorobyov, I. V. Bezyazychnaya, N. I. Martynova, D. A. Morgacheva, M. B. Belogurova, Yu. V. Dinikina

       Introduction. Central nervous system (CNS) tumors are the most common pediatric solid tumor, that need multimodality treatment approach including surgery, intensive chemotherapy (CT) and radiotherapy (RT). Due to toxicity, mostly late, RT has limited use in children, especially those under 3 years of age. The physical characteristics of proton beam therapy (PBT) minimize the risk and types of toxicity compared to photons, making it the preferred choice for pediatric use.   Aim – to analyze the experience of PBT in patients under 18 years of age with various types of CNS malignancies, the assessment of risk factors for acute and late toxicity and its clinical manifestations. Materials and methods. A retrospective analysis of 63 courses of PBT performed in 58 patients with CNS malignancies for the period from 2018 to 2022 was carried out on Proton Center of the Sergey Beresin Medical Institute. The manifestations of local and systemic toxicity (predominantly acute) were analyzed, with an assessment of the influence of age, the volume of RT, the use of previous and concomitant CT on the severity of adverse events (AE).   Results. In the study cohort, patients with embryonal CNS malignancies predominated (72.3 %). Median age was 5 years 2 months, median follow-up was 15 months. In 36 % of cases, a complete response was achieved by the start of PBT. Patients with craniospinal irradiation (CSI) prevailed (60 %). Among the manifestations of toxicity, AE grade I–II predominated. The most common AE were local reactions (dermatitis (84 %), focal alopecia (96 %)). Among systemic AE, hematological complications (84 %) were the most often occurred. A more pronounced toxicity profile was registered in the group with CSI, while concomitant CT, the patient’s age, previous CT did not significantly affect the severity of most of the assessed AE parameters (p > 0.05). The analysis of late toxic effects was difficult due to the short follow-up period, the cumulative effect of other treatment modalities on the AE’s development. The reported complications included persistent focal alopecia (14 % of cases), endocrinopathies (7 %), neurological manifestations (6 %). One (2 %) child had a severe neurological deficit, secondary epilepsy with psychomotor regression, which can also be associated with the potentiating effect of previous CT and high-dose CT.   Conclusion. The analysis of our data and literature review allows to conclude that PBT has relatively low toxicity profile, which is the determining factor for choosing this method of RT in pediatric patients. The main risk factor of AE’s was CSI. The acceptable acute toxicity of repeat PBT makes it possible to be used in pts with disease progression or relapse in case of absence of alternative therapeutic options.

  • Open Access

    First experience of total body irradiation in conditioning regimes for allogenic hematopoietic stem cells transplantation in children with acute lymphoblastic leukemia in Saint Petersburg

    by Yu. V. Dinikina, A. V. Mikhailov, M. A. Rusina, A. Yu. Smirnova, N. A. Vorob’oV, N. A. Kataev, A. V. Kubasov

    Background. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment method of refractory and recurrent forms of acute leukemia in children, while the question of choosing a conditioning regimen in order to achieve the best treatment results remains debatable. Conditioning based on total body irradiation (TbI) was confirmed to be most effective in some trials, but there are still issues of overcoming early and late toxicity, as well as difficulties in planning and routing patients.Aim. To share the experience of interdisciplinary patient management during the conditioning period with TbI inclusion in Saint petersburg, to evaluate the feasibility, toxicity and effectiveness of the method.Materials and methods. patients undergoing allo-HSCT for high risk acute lymphoblastic leukemia conditioned either with TbI (n = 12) or chemotherapy (n = 10) were included. Medical data were retrospectively analyzed with an assessment of the following transplant outcomes: HSCT-associated toxicity, the frequency and severity of infectious complications, graft versus host disease, as well as overall and event-free survival rates. we have evaluated radiotherapy plans in order to assess the compliance of radiation exposure with acceptable values for critical organs.Results. All patients with acute lymphoblastic leukemia in both groups received appropriate myeloablative conditioning. According to the study results, despite the lack of significance, we obtained differences in HSCT-associated mortality (8.3 and 30 %; p = 0.151), 2-years overall and event-free survival (66 ± 13.6 and 36 ± 16.1 %; p = 0.122) in group with TbI and HdCT respectively. It should be noted that there was a trend towards a decrease of toxic reactions frequency in case of TbI-containing regimens; however we didn’t reveal any significant differences in the number of infectious complications during post-transplant period. The median follow-up was 24.2 months and there were no signs of delayed toxicity.Conclusion. TbI-based conditioning was well tolerated with a low incidence of early and delayed toxicity, better overall and event-free survival. based on feasibility of TbI in Saint petersburg hospitals it is possible to recommend the method in routine practice, taking into account clinical indications.


  • Open Access

    Extracorporeal membrane oxygenation for acute respiratory distress syndrome in a child with central nervous system tumor

    by E. P. Evsyutina, Yu. V. Dinikina, A. Yu. Smirnova, E. E. Fedulova, A. A. Tereshina, M. M. Kirichenko, K. A. Morozov, I. I. Gorelov, A. K. Latypov, I. N. Menshugin, et al.

    The article presents the case of successful extracorporeal membrane oxygenation in severe acute respiratory distress syndrome in a child with malignant brain tumor. This method can be used in children with oncological diseases, taking into account the underlying disease and risk factors, considering strict implementation of the recommendations on concomitant therapy, laboratory control and monitoring.